GBGregory P. Bisson

Gregory P. Bisson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gregory P. Bisson has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Amita Gupta

    13Johns Hopkins University School of Medicine, Baltimore, United States

    2 shared publications
  • Andrew P. Steenhoff

    Botswana-University of Pennsylvania Partnership, Gaborone, Botswana

    2 shared publications
  • Jing Bao

    14HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, Bethesda, United States

    2 shared publications
  • Johnstone Kumwenda

    Johns Hopkins Project, Blantyre, Malawi

    2 shared publications
  • Katherine T. Steele

    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

    2 shared publications
  • Kogieleum Naidoo

    Centre for the AIDS Program of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban

    2 shared publications

Latest Publications

  • Open Access

    Redox imbalance and oxidative DNA damage during isoniazid treatment: A clinical and translational pharmacokinetic study

    by Isaac Zentner, Hyun-Moon Back, Leonid Kagan, Selvakumar Subbian, Jyothi Nagajyothi, Shashikant Srivastava, Jotam Pasipanodya, Tawanda Gumbo, Gregory P. Bisson, Christopher Vinnard

    Background: The potential for hepatotoxicity during isoniazid-based tuberculosis (TB) treatment presents a major challenge for TB control programs worldwide. We sought to determine whether pharmacokinetic exposures of isoniazid and its metabolites were related to cellular oxidation/reduction status and downstream markers of oxidative DNA damage. Methods: We performed intensive pharmacokinetic sampling among isoniazid-treated patients to determine the relative plasma exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine. Physiologically-based pharmacokinetic modeling was used to estimate liver tissue exposures during a 24-hour dosing interval for each compound. We experimentally treated HepG2 cells with isoniazid and metabolites at equimolar concentrations corresponding to these exposures for 7, 14, and 28 day periods, and performed assays related to redox imbalance and oxidative DNA damage at each timepoint. We related a urine marker of oxidative DNA damage to serum isoniazid pharmacokinetic exposures and pharmacogenetics in a clinical study. Results: Among isoniazid-treated patients, serum concentrations of hydrazine and isoniazid concentrations were highly correlated. At equimolar concentrations that approximated hepatic tissue exposures during a 24-hour dosing interval, hydrazine demonstrated the highest levels of redox imbalance, mitochondrial injury, and oxidative DNA damage over a 28-day treatment period. In a clinical validation study of isoniazid-treated TB patients, peak isoniazid serum concentrations were positively associated with a urine biomarker of oxidative DNA damage. Conclusions: Isoniazid and its metabolites share the potential for oxidative cellular damage, with the greatest effects observed for hydrazine. Future studies should investigate the clinical consequences of oxidative stress with regards to clinical episodes of drug induced liver injury during isoniazid treatment.


  • Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

    by Gregory P. Bisson, Ritesh Ramchandani, Sachiko Miyahara, Rosie Mngqibisa, Mitch Matoga, McNeil Ngongondo, Wadzanai Samaneka, Lucy Koech, Kogieleum Naidoo, Mohammed Rassool, et al.

    Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4+ T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4+ T-cell response and new opportunistic infections. Results: Of 850 enrolled, the median pre-ART CD4+ T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4+ T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4+ T-cell count and viral load for those who died (n = 43) vs. survived were 26 vs. 56 cells/μl and −2.7 vs. −2.7 log10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4+ T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01–1.42, P = .038). Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.


  • Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

    by Mina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, Xin Sun, Agnes Moses, Cynthia Riviere, Fredrick K Kirui, Sharlaa Badal-Faesen, David Lagat, Mulinda Nyirenda, et al.


  • Persistent High Mortality in Advanced HIV/TB Despite Appropriate Antiretroviral and Antitubercular Therapy: an Emerging Challenge

    by Gregory P. Bisson, Nicola Zetola, Ronald G. Collman

    Approximately 1.1 million, or 13 %, of all TB cases in 2013 were coinfected with HIV, and in some African countries, such as Botswana and Swaziland, 60–80 % of TB cases are coinfected with HIV. Effective therapies for both HIV and TB exist, yet patients presenting with TB and advanced HIV still experience high rates of morbidity and mortality despite initiation of both antitubercular and antiretroviral therapy (ART). Previous reviews and research have focused largely on TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) as a type of complicated outcome on ART in advanced HIV/TB, but recent data indicate that immunologic failure despite suppressive ART is associated with early mortality. In this review, we examine recent findings regarding early mortality in HIV/TB and emerging concepts in the pathophysiology of TB-IRIS, in order to provide an integrated view of factors determining outcomes in coinfected people as well as highlight key needs for future research and therapeutic development.


  • Open Access

    Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis

    by Gregory P. Bisson, Mooketsi Molefi, Scarlett Bellamy, Rameshwari Thakur, Andrew Steenhoff, Neo Tamuhla, Tumelo Rantleru, Irene Tsimako, Stephen Gluckman, Shruthi Ravimohan, et al.

    Background. The burden of Cryptococcus neoformans in cerebrospinal fluid (CSF) predicts clinical outcomes in human immunodeficiency virus (HIV)–associated cryptococcal meningitis (CM) and is lower in patients on antiretroviral therapy (ART). This study tested the hypothesis that initiation of ART during initial treatment of HIV/CM would improve CSF clearance of C. neoformans. Methods. A randomized treatment-strategy trial was conducted in Botswana. HIV-infected, ART-naive adults aged ≥21 years initiating amphotericin B treatment for CM were randomized to ART initiation within 7 (intervention) vs after 28 days (control) of randomization, and the primary outcome of the rate of CSF clearance of C. neoformans over the subsequent 4 weeks was compared. Adverse events, including CM immune reconstitution inflammatory syndrome (CM-IRIS), and immunologic and virologic responses were compared over 24 weeks. Results. Among 27 subjects enrolled (14 control and 13 intervention), the median times to ART initiation were 7 (interquartile range [IQR], 5–10) and 32 days (IQR, 28–36), respectively. The estimated rate of CSF clearance did not differ significantly by treatment strategy (−0.32 log10 colony-forming units [CFU]/mL/day ± 0.20 intervention and −0.52 log10 CFUs/mL/day (± 0.48) control, P = .4). Two of 13 (15%) and 5 of 14 (36%) subjects died in the intervention and control arms, respectively (P = 0.39). Seven of 13 subjects (54%) in the intervention arm vs 0 of 14 in the control arm experienced CM-IRIS (P = .002). Conclusions. Early ART was not associated with improved CSF fungal clearance, but resulted in a high risk of CM-IRIS. Further research on optimal incorporation of ART into CM care is needed. Clinical Trials Registration. NCT00976040.


  • Open Access

    Early Mortality and AIDS Progression Despite High Initial Antiretroviral Therapy Adherence and Virologic Suppression in Botswana

    by Katherine T. Steele, Andrew P. Steenhoff, Craig W. Newcomb, Tumelo Rantleru, Rudo Nthobatsang, Gloria Lesetedi, Scarlett L. Bellamy, Jean B. Nachega, Robert Gross, Gregory P. Bisson

    Adverse outcomes occurring early after antiretroviral therapy (ART) initiation are common in sub-Saharan Africa, despite reports of high levels of ART adherence in this setting. We sought to determine the relationship between very early ART adherence and early adverse outcomes in HIV-infected adults in Botswana. This prospective cohort study of 402 ART-naïve, HIV-infected adults initiating ART at a public HIV clinic in Gaborone, Botswana evaluated the relationship between suboptimal early ART adherence and HIV treatment outcomes in the initial months after ART initiation. Early adherence during the interval between initial ART dispensation and first ART refill was calculated using pill counts. In the primary analysis patients not returning to refill and those with adherence <0.95 were considered to have suboptimal early adherence. The primary outcome was death or loss to follow-up during the first 6 months of ART; a secondary composite outcome included the primary outcome plus incident opportunistic illness (OIs) and virologic failure. We also calculated the percent of early adverse outcomes theoretically attributable to suboptimal early adherence using the population attributable risk percent (PAR%). Suboptimal early adherence was independently associated with loss to follow-up and death (adjusted OR 2.3, 95% CI 1.1–4.8) and with the secondary composite outcome including incident OIs and virologic failure (adjusted OR 2.6, 95% CI 1.4–4.7). However, of those with early adverse outcomes, less than one-third had suboptimal adherence and approximately two-thirds achieved virologic suppression. The PAR% relating suboptimal early adherence and primary and secondary outcomes were 14.7% and 17.7%, respectively. Suboptimal early adherence was associated with poor outcomes, but most early adverse outcomes occurred in patients with optimal early adherence. Clinical care and research efforts should focus on understanding early adverse outcomes that occur despite optimal adherence.


  • Open Access

    A Simple Novel Method for Determining Mortality Rates in HIV Treatment Programs Worldwide

    by Gregory P. Bisson

    In this Perspective, Gregory Bisson discusses a new article by Matthias Egger and colleagues that introduces a simple method for HIV treatment programs to more accurately estimate the proportion of patients dying in the first year after ART initiation.

  • Open Access

    In-hospital mortality of HIV-infected cryptococcal meningitis patients withC. gattiiandC. neoformansinfection in Gaborone, Botswana

    by Katherine T. Steele, Rameshwari Thakur, Rudo Nthobatsang, Andrew P. Steenhoff, Gregory P. Bisson

    The clinical presentations and outcomes of cryptococcal meningitis (CM) may be associated with the cryptococcal species causing the infections. To ev


  • Open Access

    Multiple oncogenic viruses identified in Ocular surface squamous neoplasia in HIV-1 patients

    by Kenneth O Simbiri, Masanao Murakami, Michael Feldman, Andrew P Steenhoff, Oathokwa Nkomazana, Gregory Bisson, Erle S Robertson

    Background: Ocular surface squamous neoplasia (OSSN) is a rare cancer that has increased in incidence with the HIV pandemic in Africa. The underlying cause of this cancer in HIV-infected patients from Botswana is not well defined.Results: Tissues were obtained from 28 OSSN and 8 pterygia patients. The tissues analyzed from OSSN patients were 83% positive for EBV, 75% were HPV positive, 70% were KSHV positive, 75% were HSV-1/2 positive, and 61% were CMV positive by PCR. Tissues from pterygium patients were 88% positive for EBV, 75% were HPV positive, 50% were KSHV positive, and 60% were CMV positive. None of the patients were JC or BK positive.In situhybridization and immunohistochemistry analyses further identified HPV, EBV, and KSHV in a subset of the tissue samples.Conclusion: We identified the known oncogenic viruses HPV, KSHV, and EBV in OSSN and pterygia tissues. The presence of these tumor viruses in OSSN suggests that they may contribute to the development of this malignancy in the HIV population. Further studies are necessary to characterize the molecular mechanisms associated with viral antigens and their potential role in the development of OSSN.


  • Open Access

    Lost but Not Forgotten—The Economics of Improving Patient Retention in AIDS Treatment Programs

    by Gregory P. Bisson, Jeffrey S. A. Stringer

    Gregory Bisson and Jeffrey Stringer discuss the implications of a new study showing how loss to follow-up affects the effectiveness of a public sector HIV program in Côte d'Ivoire.